A PHASE 2, SINGLE-ARM, PATHOLOGIST-BLINDED STUDY USING LIVER BIOPSY SPECIMENS TO ASSESS COPPER CONCENTRATION AND HISTOPATHOLOGIC CHANGES IN PATIENTS WITH WILSON DISEASE WHO ARE TREATED WITH ALXN1840 FOR 48 WEEKS FOLLOWED BY AN EXTENSION TREATMENT PERIOD WITH ALXN1840 FOR UP TO AN ADDITIONAL 48 WEEKS.

Registry ID

ALXN1840-WD-205

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

ALEXION PHARMACEUTICALS INC

Completion date

2023-05-17

Last update

2020-07-15

Conditions

• WILSON'S DISEASE

Related clinical trials

• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, SEAMLESS, ADAPTIVE,SAFETY, DOSE-FINDING, AND PHASE 3 CLINICAL STUDY OF UX701 AAV-MEDIATED GENE TRANSFER FOR THE TREATMENT OF WILSON DISEASE

View on source registry